Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.42 |
| ▸ | KIF11 | P52732 | 2/20 | 0.41 |
| ▸ | PPARA | Q07869 | 5/20 | 0.40 |
| ▸ | PPARD | Q03181 | 3/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.40 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9035012 | 0.83 | CA1 (0.47) | CA1CA2CA9TRPV1MAOB | |
| SCHEMBL9165045 | 0.82 | NFE2L2 (0.39) | TRPV1PPARAALDH1A1 | |
| SCHEMBL6209961 | 0.80 | ALDH1A1 (0.46) | KIF11PPARAPPARGMAOBCES2 | |
| SCHEMBL11515786 | 0.79 | CA1 (0.37) | CA1CA2CA9TRPV1KIF11 | |
| SCHEMBL13802159 | 0.79 | ACHE (0.41) | CA1CA2CA9PPARAALDH1A1 | |
| SCHEMBL9035478 | 0.79 | ALDH1A1 (0.50) | CA1CA2CA9CES2CES1 | |
| SCHEMBL19477800 | 0.79 | CA1 (0.45) | CA1CA2CA9TRPV1KIF11 | |
| SCHEMBL11887280 | 0.79 | CA1 (0.45) | CA1CA2CA9TRPV1KIF11 | |
| SCHEMBL3496791 | 0.78 | PPARA (0.53) | PPARAPPARDPPARGALDH1A1 | |
| SCHEMBL1889507 | 0.78 | MEN1 (0.39) | CA1CA2CA9PPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400579-A1 | SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | GENENTECH, INC. | 2024-12-05 | — | — | US | disclosed |
| EP-4436976-A1 | SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | Genentech, Inc. (US) | 2024-10-02 | — | — | EP | disclosed |
| CN-118510783-A | Spiro modulators of cholesterol biosynthesis and their use for promoting remyelination | 基因泰克公司 | 2024-08-16 | — | — | CN | disclosed |
| WO-2023097234-A1 | SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | GENENTECH, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023097234-A1 | SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | GENENTECH, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400579-A1 | SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | MAG, NR1H2, PMP22 | CA1 3672/4885CA2 4313/4885CA9 4829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.